The Global Market for Biomarkers (Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers)

Attention: There is an updated edition available for this report.
   Single User - $3,995
   Site License (one location, 10 users) - $5,995
   Corporate License - $7,990

Published Oct 16, 2013 | 330 Pages | Pub ID: KLI5136277

The effectiveness of biomarkers has made them essential to medicine, with successful products on the market and many products in development.   This Kalorama Information report focuses on both the clinical biomarkers and research biomarkers in medicine.

Biomarkers are physiologic, genetic or biochemical parameters that provide insight into understanding disease processes and ways that medicines can work to counteract the disease.  With them, diseases are detected earlier, more effective treatments can be delivered, drug reactions reduced.  An example is creatine kinase, or CK-MB, a marker that facilitates high-energy phosphates in the body’s tissues, and can suggest a cardiovascular event when levels are high.  Other markers can identify the seriousness of tumors or signal immune system problems.

These biomarkers are valuable in assessing risk, detecting current disorders or diseases, treatment assessments, drug matching, etc. In research, biomarkers are useful for drug development and determining new markers for drug targeting.

The report will provide a market analysis for five broad areas of medical biomarkers:

  • The Market for Cancer Biomarkers (by Type of Cancer)
  • The Market for Cardiovascular and Blood Biomarkers
  • The Market for Endocrine and Immune Biomarkers
  • The Market for Infectious Disease Biomarkers (by Disease)
  • The Market for Neurological Disease Biomarkers
For each area, additional market detail is provided:
  • Segment Breakouts
  • Regional Breakout (US, EMEA, Other)
  • Market Share
Market analysis in this report considers both the epidemiological considerations and the size patient groups, available biomarkers in each segment, and estimated percentage of biomarker use in patient treatment.
The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers. 

All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Market data pertains to the world market at the manufacturers’ level. The base year for data was 2013. Historical data was provided for the years 2008 through 2012, with forecast data provided for 2014 through 2018. Compound annual growth rates (CAGRs) are provided for the 2008-2013 and 2013-2018 periods for each segment covered.

Basic competitor summaries are included in each segment. The forecasted market analysis for 2014-2018 was largely based on demographic trends, new developments, biomarker development, company performance trends, merger and acquisitions, and global expansion.
Company profiles in this report include:
  • 20/20 GeneSystems
  • Abbott Laboratories
  • Affymetrix
  • Agendia
  • Alere
  • Beckman Coulter
  • Becton Dickinson
  • Biocartis SA
  • Biodesix
  • bioMerieux
  • BioReference Laboratory
  • bioTheranostics
  • CardioDX
  • Celera Alameda
  • Clarient
  • deCODE Genetics
  • DiaGenic
  • Genomic Health
  • Genoptix Medical Laboratory
  • Illumina
  • Johnson & Johnson
  • Life Techologies
  • Memory Dx
  • Myriad Genetics
  • Nanostring Technologies
  • OPKO Health
  • Provista Dx
  • Qiagen
  • Roche
  • Seimens Healthcare
  • Singulex
  • Tethys Bioscience
  • Thermo Fisher Scientific
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times